Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical - Takeaways - MDSpire

Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical

  • By

  • Zin W. Myint

  • Riham H. El Khouli

  • Bryan P. Lemieux

  • Charles A. Kunos

  • May 4, 2026

  • 0 min

Share

  • 1

    An 80-year-old man developed gangrene after receiving Sn-117m-DTPA for skeletal metastases from castration-resistant prostate cancer.

  • 2

    The patient experienced significant pain relief from skeletal metastases but later developed severe complications including leukopenia and gangrene.

  • 3

    Emergent amputations were performed due to tissue necrosis, but the patient ultimately succumbed to sepsis from aspiration pneumonia.

  • 4

    Gangrene is a rarely reported serious adverse event following radiopharmaceutical treatment, necessitating prompt intervention.

  • 5

    Subtle skin integrity issues post-treatment may be more common than recognized and should be monitored in clinical settings.

Original Source(s)

Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical

  • by Zin W. Myint, Riham H. El Khouli, Bryan P. Lemieux, Charles A. Kunos

  • May 4, 2026

Related Content

DeepInsight-Net: a CBAM-enhanced ResNet50 framework with focal loss for robust cervical cancer classification on multi-center datasets

Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis

Mass Spec Roundup: Proteins, Lipids, Pitcher Plants, and Coffee

This week’s roundup explores hidden chemistry in the dark proteome, forest soils, lipid binding in cells, and pitcher plant food webs

  • May 13, 2026

  • 7 min